Figure 2.

Median and Cumulative Incidence of Myocardial Injury by Chemotherapy Cycle

This figure summarizes the changes in cTn across chemotherapy cycles, with samples were taken at baseline (before cycle 1), <72 hours before each subsequent cycle, and 1 month after the last dose of anthracycline. Solid lines represent median (Q1-Q3) troponin levels, and dashed lines show the cumulative percentage of patients developing myocardial injury (elevated cardiac troponin) at each timepoint. (A) Cardiac troponin T (cTnT) levels and (B) cardiac troponin I (cTnI) levels, both illustrating the increasing risk of myocardial injury with progressive anthracycline doses. Notably, there is no attenuation of this risk with enalapril treatment. Furthermore, the cumulative rates of myocardial injury differ between the cTnT and cTnI assays, markedly underscoring the variable sensitivity of these biomarkers.